The healthcare reform bill currently winding its way through the U.S. Congress may make the shares of some health and drug companies more attractive, Reuters reports, citing Barron’s.
Stocks in the healthcare sector are trading at discounts even though the final version of the Obama administration’s proposed reform represents less of an important change than expected, Barron’s wrote in its Monday edition, citing Rockefeller & Co analyst David Song, Reuters reports.
Most healthcare companies will benefit from the incentive the bill gives providers to give more care, Barron’s wrote.For example, diagnostic-testing company Laboratory Corp of America may be priced conservatively.
Drugmakers Amgen, which has a new pill for osteoporosis, and Cheshire-based Alexion Pharmaceuticals, which has an approved drug for a rare blood disorder, should both gain from certain provisions of the Senate bill dealing with marketing exclusivity, Barron’s wrote, citing Song.
